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Objective
To review the long-term follow-up data from the authors’ insti-
tutional experience of 62 patients with locally advanced breast
cancer (LABC) treated with a uniform multimodality regimen.
The authors determined the rate of breast preservation, the
disease-free and overall survival, and the factors associated
with locoregional and distant recurrent disease.
Summary Background Data
It remains a challenge to achieve local and distant control of
LABC. Over the last decade, preoperative or neoadjuvant
chemotherapy has emerged as the standard of care for these
patients. Successful tumor downstaging has been associated
with increased rates of breast-conserving therapy (BCT), but
the overall effect on long-term survival remains to be seen.
Methods
This study examines a cohort of 62 patients with LABC
treated at the authors’ institution from 1992 to 1998. The uni-
form treatment regimen consisted of neoadjuvant doxorubicin
(Adriamycin), followed by operation (BCT if sufficient clinical
downstaging), followed by non-cross-resistant cyclophospha-
mide/methotrexate/5-fluorouracil, followed by radiation ther-
apy. Treatment was both dose-intensive and time-intensive,
with a total treatment time of 32 to 35 weeks.
Results
In this patient population, the median age was 44 years, with
approximately two thirds white patients and one third African
American. Eighty-two percent of patients were clinical stage III at
presentation, 13 patients had T4d inflammatory cancers, and 3
patients were stage IV at diagnosis. Eighty-four percent of pa-
tients demonstrated a significant clinical response to doxorubi-
cin. Twenty-eight patients had sufficient clinical downstaging to
attempt BCT, and 22 (45%) of 49 noninflammatory patients un-
derwent successful BCT. Pathologic complete response was
seen in 15% of patients. Median follow-up for the cohort was 70
months. The local recurrence rate was 14%, including two ipsi-
lateral breast tumor recurrences (10%) in the BCT patients.
Seven (12%) patients developed a new primary cancer in the
contralateral breast. Distant metastases occurred in 18 (31%)
patients, and the 5-year overall survival rate for the cohort was
76%. Furthermore, in the patients who underwent an attempt at
BCT, the survival rate was 96% at 5 years.
Conclusions
Dose-intensive and time-intensive multimodality neoadjuvant
therapy was successfully administered to a mixed racial group
over shortened times. Patients who had sufficient clinical
downstaging to allow BCT have the best long-term outcome.
Patients who required mastectomy are at a higher risk of re-
lapse, as well as the development of new contralateral can-
cers, yet have 5-year survival rates of over 50%.
Despite efforts at early detection, locally advanced breast
cancer (LABC) remains both a prevalent clinical problem
and a challenge for achieving local and distant control of
disease. In the past, many of these patients have been
considered to be inoperable because of the sheer volume of
their tumors and the belief that they would soon succumb to
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neoadjuvant (preoperative) chemotherapy has emerged as
the standard of care for patients with large primary tumors
or matted axillary nodal metastases.1 The rationale for neo-
adjuvant therapy is based on data from randomized and
nonrandomized clinical trials that have demonstrated suc-
cessful tumor downstaging and correlated the response to
chemotherapy with patient outcome.2 Two large random-
ized trials, the NSABP B18 and the EORTC 10902, com-
pared preoperative versus postoperative chemotherapy in
primary operative breast cancer.2,3 While survival rates
were equivalent in both arms of each trial, the tumor down-
staging afforded by preoperative chemotherapy resulted in
increased rates of breast-conserving therapy (BCT). Based
on the data from smaller breast tumors, investigators have
extended BCT to larger tumors that are successfully down-
staged with neoadjuvant chemotherapy and report satisfac-
tory rates of local control of disease.4,5
In 1992, our group at the University of North Carolina-
Lineberger Comprehensive Cancer Center (UNC-LCCC)
began a trial for patients with LABC that used a particular
regimen of aggressive neoadjuvant chemotherapy, surgery,
and radiotherapy. Sixty-two patients were treated with dose-
intensive and time-intensive chemotherapy. BCT was per-
formed if indicated by successful tumor downstaging. In
this report, we present the long-term outcomes of this study,
having achieved a median follow-up of 70 months. We have
examined the sites of recurrence and metastasis to deter-
mine the disease-free and overall survival rates, the factors
associated with BCT, the factors associated with local and
distant relapse, and the relationship of local downstaging to
outcome.
METHODS
Breast cancer patients with primary tumors greater than 5
cm (T3), with skin or chest wall involvement (T4), or with
matted axillary adenopathy (N2) were defined as having
LABC and were eligible for the study. The diagnosis was
obtained by either a fine-needle aspiration or a tissue biopsy.
All of the patients were treated at UNC-LNCC with a
uniform multimodality regimen that included dose- and
time-intense neoadjuvant doxorubicin (90 mg/m2 given
over 48 hours every 2.5 weeks for four cycles) followed by
surgery. BCT was performed when there was sufficient
downstaging to a tumor size of 4 cm or less and segmental
mastectomy could be achieved with acceptable cosmetic
result. All patients had a complete (levels I–III) axillary
dissection. Within 14 to 21 days postoperatively, additional
adjuvant dose- and time-intense chemotherapy was initiated
with a combination of cyclophosphamide, methotrexate,
and fluorouracil (CMF) at escalating doses up to 1,200
mg/m2 cyclophosphamide, 900 mg/m2 methotrexate, and
1,200 mg/m2 fluorouracil (termed the dose-dense modified
Bonadonna regimen). G-CSF support was given to all pa-
tients. Adjuvant radiotherapy followed the CMF. Tamox-
ifen (10 mg twice daily for 5 years) was given to all patients
greater than 50 years old at the time of diagnosis, or younger
patients with estrogen receptor (ER)-positive or progester-
one receptor (PR)-positive tumors by biochemical assay or
immunohistochemistry. Our treatment protocol emphasized
timely completion of all modalities of therapy within 32
weeks, with minimal interval between modalities.
The case report forms and medical charts provided clin-
ical and outcomes data for this study. Tumor measurements
and response assessments were performed by several phy-
sicians, and when there was more than one measurement,
the medical oncologist’s measurements and response as-
sessments were used. Clinical responses were defined by the
primary tumor response and were categorized as follows:
complete response (CR)  complete clinical and radio-
graphic resolution of tumor; partial response (PR)  50% or
greater diminution of bidimensional tumor; minimal re-
sponse (MR)  25% to 50% diminution of tumor; stable
disease (SD)  no more than 25% increase or decrease in
tumor size; progressive disease (PD)  more than 25%
increase in tumor. Since patients with a poor response to
chemotherapy could receive a second neoadjuvant regimen,
response was assessed uniformly after doxorubicin and did
not include the response to a second regimen. A pathologic
complete response was defined as no evidence of invasive
cancer in the breast or axilla. Axillary nodal status was
grouped as follows: 0 involved lymph nodes after chemo-
therapy, 1 to 3 lymph nodes, 4 to 9 lymph nodes, and 10
lymph nodes. ER and PR were routinely assayed using
either a biochemical assay or immunohistochemistry. For
the purposes of this analysis, patients with borderline ER or
PR were grouped with “positive.” Most patients had ER,
PR, and tumor grade evaluated pretreatment, although some
had these analyses performed on the final surgical specimen.
When receptors and tumor grade were assessed both before
and after therapy, the pretreatment measure was used. Out-
comes data were obtained from protocol follow-up forms,
medical records, and the tumor registry. Relapse or disease-
free survival was calculated as the time from primary tumor
diagnosis to time of last follow-up, development of either
in-breast or chest wall local recurrences (for locoregional),
development of systemic metastases (for distant disease), or
death.
Statistical Analyses
We used logistic regression to examine factors associated
with the attempt of BCT in noninflammatory cancers. We
used Cox regression to evaluate possible predictors in the
time-to-event outcomes of locoregional relapse-free sur-
vival, distant disease-free survival, and overall survival.
Survival curves were calculated using the Kaplan-Meier (or
product limit) method. We used the log-rank test for differ-
ences between survival curves. All analyses were performed
using JMP 3.2.1 and SAS version 8.2 (SAS Institute Inc.,
Cary, NC).
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RESULTS
Patient Demographics, Tumor Staging,
and Treatment
Between 1992 and 1998, 62 patients with LABC were
treated with this uniform multimodality treatment. Median
age was 44 years (Table 1). Approximately two thirds of the
patients were white and one third African American. Fifty-
one (82%) of the patients were clinical stage III at diagnosis,
with 34 stage IIIA and 17 stage IIIB. Three patients with
LABC were considered to be stage IV at diagnosis. In
addition, our cohort included 13 (21%) patients with inflam-
matory cancer, defined as tumor stage T4d (12 stage IIIB, 1
stage IV). Forty-five percent of patients were ER positive
and 69% were premenopausal or perimenopausal. Median
follow-up for the cohort was 70 months (range 35–117).
Fifty-eight (94%) of patients received neoadjuvant doxo-
rubicin, while four patients received both the single agent
doxorubicin and the CMF neoadjuvantly. After neoadjuvant
chemotherapy, all patients underwent surgical resection of
the primary tumor and a full axillary dissection, although
one declined surgery until undergoing a mastectomy 2 years
after diagnosis. Two patients were converted to convention-
al-dose AC for their neoadjuvant therapy due to toxicity to
dose-intense doxorubicin. One patient declined adjuvant
CMF. Fifty-nine (95%) of the 62 patients received radiation
therapy. The radiation was administered postlumpectomy in
22 patients, postmastectomy in 33, and before surgery in 4
patients in whom operability was uncertain after all chemo-
therapy. Thirty-four received tamoxifen, including, in that
era, 11 of the 34 who had ER-negative tumors. Eight of the
36 patients with ER-positive tumors declined or did not
tolerate tamoxifen.
Clinical Response to Neoadjuvant
Chemotherapy
Overall, 84% of patients demonstrated a significant clin-
ical response to chemotherapy. There was a complete clin-
ical and mammographic response to doxorubicin in 13
(22%) of 58 measured responses. Thirty-six patients (62%)
had a partial response while 8 (14%) had a minimal re-
sponse and one patient had stable disease. No patient pro-
gressed on dose-intense doxorubicin.
Surgical Treatment and Final Pathologic
Staging
A total of 28 (45%) patients had sufficient clinical down-
staging to permit an attempt at BCT by performing a segmental
mastectomy. Of these patients, 22 (79%) had successful BCT,
while 6 (21%) required completion mastectomy for positive
pathologic margins after segmental mastectomy.
Thus, in this cohort, 35% of all patients had breast pres-
ervation. As previously noted, 13 patients had inflammatory
(T4d) disease and were never considered candidates for
BCT, regardless of clinical response. If this subgroup is dis-
counted, BCT was attempted in 28 (57%) of 49 noninflamma-
tory patients, with successful conservation in 22 (45%).
Pathologic complete response was seen in nine (15%)
patients. Six were among the patients with BCT, represent-
ing 27% of the patients with conserved breasts, and 3 were
among the modified radical mastectomy (MRM) group,
representing 8% of the mastectomy group. There was no
axillary lymph node involvement after chemotherapy in 21
(34%), 1 to 3 involved lymph nodes in 16 (26%), 4 to 9
lymph nodes in 16 (26%), and 10 involved lymph nodes
in 9 (14%).
We analyzed the data to determine what clinical factors
predicted for the ability to attempt BCT in these patients.
We excluded the 13 patients with T4d inflammatory tumors,
as they were never candidates for BCT, and analyzed the
factors associated with attempting BCT. Factors signifi-
cantly associated with the ability to attempt BCT included
initial tumor size and posttreatment tumor size and the
clinical response to chemotherapy (Table 2). Age, race, and
ER status were not significantly associated. When this anal-
ysis was repeated only for patients with successful BCT,
similar results were obtained, although ER negativity was
also significantly (P  .02) associated with successful BCT.
Outcome Analyses
Three patients in this cohort had clinical stage IV disease
with distant metastases at diagnosis and were excluded from
Table 1. PATIENT DEMOGRAPHICS AND
TUMOR STAGING
Total 62
Median age (range) 44 (23–66)
Race
Caucasian 41 (66%)
African American 19 (31%)
Other 2 (3%)
Stage
IIB (all T3N0) 8 (13%)
IIIA 34 (55%)
T3 N1 24 (39%)
T0-2 N2 6 (10%)
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outcome analysis; thus, our analysis was based on a total of
59 patients.
Locoregional Recurrence
Eight (14%) patients suffered 11 locoregional recur-
rences, including in-breast, chest wall, axillary, or supracla-
vicular lymph node (Table 3). Overall, a low percentage of
locoregional recurrences occurred in both the BCT group
(2/21, 10%) and in the MRM group (6/38, 16%). Two
(10%) ipsilateral breast tumor recurrences occurred in the
BCT group, and one of these recurrences was also associ-
ated with a supraclavicular nodal recurrence. There were
five chest wall recurrences in the MRM group, including
one patient who declined mastectomy for 2 years. One of
the five patients with chest wall recurrences had declined
radiotherapy, and two of the five patients with chest wall
recurrences had inflammatory cancers. Table 4 depicts fac-
tors associated with locoregional recurrence. In Cox regres-
sion analysis, patients with inflammatory disease, higher
pretreatment stage, or poor response to chemotherapy, and
those who were not candidates for BCT were more likely to
suffer locoregional recurrences.
Among those with locoregional recurrence, the median
time to recur was 23 months (range 9–55). Four (50%) of
the eight patients with locoregional recurrence also devel-
oped distant metastases at 1 month and 1, 27, and 61
months later.
Contralateral New Primary Breast Cancers
In this group of high-risk patients, there was an elevated
rate of new primary cancers developing in the contralateral
breast. Overall, seven (12%) patients developed new con-
tralateral breast primaries during the follow-up period (see
Table 3). Six of these cancers occurred in the MRM group,
representing a rate of 16%, indicating an unusually high
incidence of second primaries in this group. In contrast,
only one new contralateral primary was detected in patients
who underwent BCT. No BCT patient developed a new
primary cancer in the conserved breast.
Distant Relapse and Death
The Kaplan-Meier curves for these 59 patients reveal
outstanding distant disease-free survival and overall sur-
vival (Fig. 1). At a median follow-up of 70 months, only 19
(32%) developed systemic metastases, and 18 (30%) died.
Seventeen of 18 deaths occurred in patients who had re-
lapsed, 16 systemically and 1 locoregionally (chest wall).
Among those patients with distant disease, median overall
survival from diagnosis was 54 months (range 12–112).
Only two patients died without evidence of distant metas-
tases. The median time to developing distant metastases was
33 months (range 11–96). The 5-year overall survival for
the entire patient cohort was 76% (95% confidence interval
65–88%).
The most common sites of distant relapse included bone,
central nervous system, lung, lymph node, and liver, with
Table 2. PROGNOSTIC FACTORS
ASSOCIATED WITH ATTEMPT AT BREAST
CONSERVATION IN NONINFLAMMATORY




(95% CI) P Value
Age 0.97 (0.91, 1.03) .34
Race 1.40 (0.40, 4.70) .61
ER-negative 0.32 (0.08, 1.15) .08
Pretreatment tumor size 0.96 (0.92, 0.99) .03*
Posttreatment tumor size 0.91 (0.84, 0.98) .02*
Clinical chemotherapy response 0.23 (0.07, 0.80) .02*
* Significant at the   0.05 level.








Patients with recurrence 8 (14%) 2 (10%) 6 (16%)
Site*
IBTR 2 2 —
Chest wall 5 — 5
Axilla 1 0 1
Supraclavicular LN 3 1 2
New primary
Ipsilateral 0 0 —
Contralateral 7 (12%) 1 (5%) 6 (16%)
* Some patients had more than one site of locoregional recurrence.
Table 4. PREDICTORS OF
LOCOREGIONAL RELAPSE-FREE




(95% CI) P Value
Age 0.96 (0.91, 1.01) .08
Menopause 0.97 (0.37, 2.52) .95
Race 0.54 (0.20, 1.48) .23
ER-negative 0.45 (0.17, 1.17) .10
Inflammatory 3.28 (1.29, 8.39) .01*
Pretreatment stage 3.15 (1.43, 6.91) .004*
Pretreatment tumor size (cm2) 1.06 (0.99, 1.02) .32
Pretreatment nodal status 1.38 (0.91, 2.08) .13
Response rate 2.50 (1.21, 5.04) .01*
Posttreatment tumor size (cm2) 1.04 (1.01, 1.05) .004*
BCT attempt 0.20 (0.07–0.60) .004*
BCT success 0.31 (0.10–0.94) .04*
* Significant at the   0.05 level.
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soft tissue, skin, and ovary involved less frequently. Table 5
illustrates factors associated with distant disease-free and
overall survival. Using Cox regression modeling, becoming
a BCT candidate after neoadjuvant chemotherapy was the
strongest predictor of long-term survival. Intriguingly, this
was a stronger predictor than actual successful BCT, since
none of the six patients who went on to completion mas-
tectomy after initial efforts at conservation relapsed system-
ically. Other significant factors for overall and distant dis-
ease-free survival included pretreatment clinical stage,
posttreatment tumor size, inflammatory disease, successful
completion of BCT, and locoregional recurrence. Patho-
logic complete response was uncommon (nine patients,
15%) and was not significantly associated with outcome,
although response to chemotherapy and pathologic nodal
status after chemotherapy were associated with increased
distant disease-free survival.
Finally, we analyzed the outcomes of three subgroups of
this cohort of 59 patients: patients with locally advanced,
noninflammatory breast cancers who were BCT candidates
after neoadjuvant chemotherapy (n  27), patients with
noninflammatory cancers who underwent MRM (N  20),
and patients with inflammatory breast cancers treated with
mastectomy after chemotherapy (n  12). As expected, the
LABC patients without inflammatory disease who were
BCT candidates after neoadjuvant chemotherapy had an
excellent long-term distant disease-free and overall progno-
sis, with a 5-year overall survival rate of 96% (Fig. 2;
log-rank test among groups P  .007 for distant disease-free
survival, P  .002 for overall survival). The BCT candi-
dates had a significantly better outcome than patients who
did not achieve tumor downstaging sufficient to consider
BCT, who had a prognosis similar to the inflammatory
cohort. In the noninflammatory patients who underwent
MRM, the 5-year overall survival rate was 51%. Further-
Figure 1. Kaplan-Meier survival curves for distant disease-free (A) and
overall (B) survival in the entire patient cohort. This figure analyzes the
survival of 59 patients, excluding 3 patients who presented with LABC
and stage IV disease.
Table 5. FACTORS PREDICTING DISTANT DISEASE-FREE SURVIVAL (DDFS) AND
OVERALL SURVIVAL (OS) (BY UNIVARIABLE COX REGRESSION)
Prognostic Factor
DDFS OS
Hazard Ratio (95% CI) P value Hazard Ratio (95% CI) P value
Age at diagnosis 0.97 (0.92, 1.02) .19 0.97 (0.92, 1.02) .18
Inflammatory 3.08 (1.15, 8.28) .03* 3.41 (1.23, 9.43) .02*
ER-negative 0.75 (0.29, 1.89) .54 0.52 (0.18, 1.48) .22
Pretreatment stage 3.12 (1.39, 6.99) .006* 2.83 (1.24, 6.44) .01*
Response to chemotherapy1 2.05 (1.14, 3.70) .02* 1.65 (0.89, 3.05) .11
Posttreatment tumor size 1.04 (1.02, 1.06) .006* 1.03 (1.01, 1.06) .03*
Breast conservation attempted 0.27 (0.07, 0.66) .007* 0.15 (0.04, 0.53) .003*
Breast conservation succeeded 0.34 (0.11, 1.02) .05* 0.22 (0.06, 0.78) .02*
Pathologic CR 0.53 (0.12, 2.32) .40 0.74 (0.20, 2.70) .65
Pathological nodal status after chemotherapy 1.65 (1.08, 2.52) .02* 1.47 (0.94, 2.29) .09
Locoregional recurrence 3.03 (1.09, 8.44) .03* 3.93 (1.45, 10.7) .007*
* Significant at the   0.05 level.
1 Assessed as CR, PR, MR, SD, or PD to doxorubicin alone.
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more, although inflammatory breast cancer carries a high
risk of relapse, there was a 67% 5-year overall survival
among the 12 inflammatory breast cancer patients treated
with aggressive multimodality therapy. Thus, this dose- and
time-intensive multimodality treatment regimen offered sig-
nificant rates of long-term survival even in patients who had
the extremes of LABC.
DISCUSSION
This study reports mature data from a cohort of patients
with LABC treated with a uniform regimen and followed
for a median interval of over 5 years. Our results demon-
strate that patients with LABC can achieve outstanding
control of disease and long-term survival by undergoing a
dose- and time-intensive regimen of neoadjuvant chemo-
therapy. These data provide evidence that BCT can reason-
ably be accomplished in up to 45% of patients with nonin-
flammatory LABC. Furthermore, the tumor response to
chemotherapy can help identify the subgroup of LABC
patients with a more favorable long-term prognosis.
It is well established that neoadjuvant chemotherapy can
effectively downstage the primary breast cancer in patients
with LABC.1,4–9 However, in these patients as a whole, the
extent of the survival advantage provided by neoadjuvant
therapy remains less clear. In most larger studies of patients
with LABC, the 5-year survival rates range from approxi-
mately 20% to 55%.10–12 The patients in this series repre-
sent the entire clinical spectrum of LABC, including a group
of T4d inflammatory cancers. Despite this diversity, the
entire group had 5-year disease-free and overall survival
rates of over 70%. This suggests that the treatment regimen
changed the natural history of the disease in the majority of
patients.
The subgroup of patients who had the most favorable
outcomes represented those who had the best clinical re-
sponse to the doxorubicin. This finding is similar to other
reports that correlated response in the breast with long-term
outcomes.7,13–15 In fact, some investigators have found that
patients who had a pathologic complete response (pCR) had
the best outcomes.7,13 In our series, only nine patients had a
pathologic complete response, and this did not correlate
with long-term outcome. However, in our series, the stron-
gest predictor of long-term survival was whether these
patients had sufficient clinical downstaging such that BCT
could be attempted. This likely reflects a surrogate marker
for the response rate of the tumors to the doxorubicin. In
these 28 patients offered BCT, there have been only three
deaths during the long follow-up period of this study and the
5-year overall survival rate is 96%. These data strongly
argue not only that BCT is appropriate in suitably down-
staged patients, but also that this subgroup of patients has
been selected for an excellent overall outcome.
The BCT rate of 45% in this series is higher than other
studies that have examined neoadjuvant therapy in T3 and
T4 tumors, suggesting that multi-modality therapy, com-
bined with an aggressive BCT attempt, can save more
breasts in this group. The NSABP B-18 study compared
preoperative versus postoperative doxorubicin/cyclophos-
phamide chemotherapy in 1,523 women with operable, ear-
ly-stage (T1–3) breast cancer. Preoperative chemotherapy
was associated with increased lumpectomy rates compared
to postoperative chemotherapy (67% vs. 60%, P  .002)
when examining the entire cohort of patients.16 However,
the patients with T3 tumors who underwent preoperative
chemotherapy had a 22% rate of breast conservation. In the
subsequent (B-27) neoadjuvant study, there was a slightly
lower rate of BCT than the B-18, but this trial consisted of
larger tumors.17 In a series of 89 patients with stage III
breast cancer from the University of Michigan, 28% were
treated with BCT.14 Finally, a French group reported a
Figure 2. Kaplan-Meier survival curves for distant disease-free (A) and
overall (B) survival in three subgroups of the LABC patients. These
Kaplan-Meier curves illustrate outcomes among patients with locally
advanced noninflammatory breast cancers who were breast-conserva-
tion candidates after neoadjuvant chemotherapy (BCT) versus those
who were not conservation candidates (MRM). These are compared
with survival curves for inflammatory breast cancer patients, all of whom
were treated with mastectomy after chemotherapy.
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breast conservation rate of 62% in 97 stage II and III
patients treated with neoadjuvant chemotherapy.15
This group of patients had a 14% long-term local recur-
rence rate, even with a significant number of inflammatory
cancers. Notably, despite the large and locally extensive
nature of the primary tumors in this study, in-breast tumor
recurrence occurred in only 10% of the 22 patients with
conserved breasts. We have included supraclavicular lymph
node metastases as locoregional disease because this site
was included within our radiation ports and was treated with
curative intent. Other groups consider supraclavicular
lymph node metastases to be locoregional disease and not
distant metastatic disease because of a more favorable long-
term outcome.18 Not surprisingly, half of the patients with
local recurrence also developed distant metastatic disease,
suggesting the local recurrence was a manifestation of ag-
gressive biologic behavior of the tumor. Intriguingly, the
strongest factor associated with reduced rates of local re-
currence was an attempt at BCT, again illustrating the
favorable outcomes in this subgroup of patients. In contrast,
the patients who required mastectomy had an unusually
high rate of developing contralateral new primary cancers,
suggesting that their other breast also has a persistent high
risk of cancer.
The chemotherapy regimen in this study focused both on
dose intensity and time intensity. In particular, the time
interval between surgery and the beginning of the next
course of non-cross-resistant chemotherapy was kept as
short as possible, often beginning 2 weeks after operation.
There is experimental evidence that the actual excision of
the primary tumor may augment a systemic response that
enhances residual tumor growth, and this has implications
in the timing of adjuvant chemotherapy.19,20 Patients toler-
ated this quick return to chemotherapy well, with no evi-
dence of major wound healing problems. Furthermore, the
entire time of treatment was 32 to 35 weeks, including all
three treatment modalities. This contrasts to other neoadju-
vant studies where the chemotherapy treatments alone to-
taled up to 52 weeks.14
Finally, the chemotherapeutic regimen used in this study
predated the era of the taxanes that are now being used in
neoadjuvant regimens with good efficacy.17,21 We have
evolved from our high-dose CMF regimen to one that
incorporates a taxane. Our current neoadjuvant approach to
LABC uses doxorubicin/cyclophosphamide followed by
paclitaxel and Herceptin for HER-2-positive tumors. Before
treatment, the tumors are marked by the mammographers so
that their sites can be identified even with complete clinical
responses.22 Based on these data from our initial trial, we
hypothesize that treating the patients to the best clinical
response will provide the best outcome.
In conclusion, neoadjuvant chemotherapy provides a sig-
nificant survival advantage to patients with LABC. Those
patients who have clinical downstaging are candidates for
BCT and have the best long-term outcome. Patients who
require mastectomy are at a higher risk of relapse as well as
development of new, contralateral cancers, yet have 5-year
survival rates of over 50%. Thus, dose-intense and time-
intense neoadjuvant chemotherapy should be standard of
care for patients with LABC.
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DISCUSSION
DR. TIMOTHY J. EBERLEIN (St. Louis, MO): The past 10 years has seen
an increase in neoadjuvant chemotherapy protocols in breast cancer. This
study has been beautifully presented by Dr. Cance and is unique in two
regards. First is the neoadjuvant regimen dose-intensive as well as time-
intensive; that is, repeating the Adriamycin every 2.5 weeks. In fact,
completion of all modalities occurred within 32 weeks in most of the
patients, in contrast to the usual 52-week regimen in most of our neoad-
juvant trials. The second unique feature of the study is the long-term
follow-up, with the median of almost 70 months.
Dr. Cance and his colleagues have shown superb results. In patients with
locally advanced breast cancer without inflammatory disease who were
breast-conserving therapy candidates after neoadjuvant therapy, the overall
5-year survival is an astounding 96%. In fact, even in the patients with
inflammatory breast cancer there is an impressive 67% survival.
This brings me to my first question. What is the toxicity of this regimen?
It appeared that there were no treatment dropouts. Is this true? Other than
the G-CSF, that you mentioned in your presentation and in the manuscript,
to support the postoperative CMF regimen, were there other difficulties
treating these patients?
I have two questions with respect to survival. In the noninflammatory
patients who underwent modified radical mastectomy, the 5-year overall
survival rate was 51%, even less than the 67% 5-year overall survival for
the inflammatory breast cancer patients. Was this due to chemoresistance?
Were you able to identify any molecular markers that predicted response or
nonresponse to the neoadjuvant therapy, such as herz-neu?
Even more impressive than the overall survival is the fact that no patient
with breast-conserving therapy developed a new primary in the conserved
breast. However, you had seven patients in the entire cohort who had new
contralateral breast primaries, only one of these in patients who underwent
breast-conserving therapy. Again, do you have an explanation for this
observation? And is it related to the responsiveness of patients to the
chemotherapy?
Finally, as I mentioned, these are impressive results. However, since you
instituted this treatment regimen, new drugs such as taxanes and new
molecular markers such as herz-neu and others have been identified. So
would you recommend for us the best-case current regimen that we all
might care to use in our own institutions?
Once again I would like to congratulate you and your group for an
outstanding study and for contributing to breast-conserving therapy in
women who present with advanced breast cancer.
PRESENTER DR. WILLIAM G. CANCE (Chapel Hill, NC): To answer Dr.
Eberlein’s first question, there was toxicity in this group. It tended to be
relatively mild grade III toxicity. There were rare patients that did develop
severe toxicities, and three patients did not get the complete course of the
chemotherapy. The toxicity was largely related to bone marrow suppres-
sion, even though they were supplemented with G-CSF. It was a tolerable
regimen, but this high-dose chemotherapy did have side effects for some of
these patients.
You asked about the difference between the noninflammatory patients
who underwent mastectomy and the patients with inflammatory disease. I
agree that this likely reflected chemoresistance. Again, we selected for
those patients as being nonresponders, and that would seem to indicate
chemoresistance, although it is hard to establish definitive proof.
Dr. Eberlein asked about molecular markers, which is the next part of
our study. When these patients were being enrolled, we weren’ t routinely
measuring the molecular markers that are standard today. The trial was
begun in the pre-HER-2 era. Current efforts are focusing on the determi-
nation of molecular markers in these patients at various times during their
treatment.
The contralateral cancer rate likely relates to chemoresistance and prob-
ably also to some as-yet-undefined genetic defects. One additional issue in
the neoadjuvant patients is that some of them have strong family histories
of breast cancer. During the first phase of their neoadjuvant treatment,
many are getting genetically tested, which will help them determine what
operation they ultimately elect.
The current regimen that we recommend involves the use of a taxane. I
think that the high-dose CMF was standard back in 1992, but has been
replaced by the combination of Adriamycin and Cytoxan along with a
taxane. In our current regimen, we are focused on the molecular markers.
So, we are doing pretreatment biopsies and have moved to surgery after the
second non-cross-resistant chemotherapy so that we can get two biopsies
during treatment plus the final surgical specimen, to look at chemoresis-
tance. In addition, we have added Herceptin in the HER-2-positive patients.
Finally, one issue to watch is that the estrogen receptor-positive patients
do not seem to be responding as well to a taxane as estrogen receptor-
negative patients. In the ER-positive, HER-2-negative patients, we are
considering going back to the CMF regimen as the second chemotherapy
treatment.
DR. WILLIAM C. WOOD (Atlanta, GA): Two pet peeves. Small breast
cancer trials and discussants who use the podium to present their own
studies. So please indulge my reference to our intergroup study of 111
stage III patients with 9.4 years of follow-up, neoadjuvant chemotherapy of
the same agents at the same dose that you gave, although less time-intense,
manuscript in preparation by Dave Duggin. I mention it only to praise the
study that we have just heard.
Fifty-nine stage III tumors may sound like a small study. But compared
to 111 study patients that took three cooperative groups the same period of
time to accrue, and you realize what an accomplishment this is from a
single institution. Seventy-four percent major response rate in the inter-
group series compares with Dr. Cance’s 84% major response rate. A
median survival of just over 50% in our group trial compares with the 76%
that you achieved in this trial. Not only that, but a 45% breast-conserving
rate in stage III breast cancer has to be compared with the usual 20% to
30% breast-conserving therapy rate even with modern induction regimens.
And you didn’ t achieve it by pushing indications, as demonstrated by only
a 10% in-breast failure rate after this.
So I appreciated receiving this manuscript in advance. It has an excellent
discussion. I concur with your conclusions as outlined in the subtitle of
your paper. I really loved everything until you showed your conclusions
here, and then I have a quibble. I am not convinced that you have
demonstrated that multimodality neoadjuvant therapy provides a survival
advantage within this population, or the time intensity of treatment is
clearly the factor that is responsible for your suburb results.
Three questions:
The 12% incidence of contralateral breast cancer you report in 6 years is
more than twice the rate that you would expect in this age group. Could
some of these have been metastases? Were all clearly arising in a back-
ground of in situ disease?
Secondly, there are 62 patients. You appropriately excluded the three
who were stage IV, but you included eight as locally advanced disease who
were stage II rather than stage III breast cancer. I suspect you may have
already looked at the effect this may have had on your outcomes. And if
you have, I wonder if you could share that with us.
Thirdly, as you demonstrated again, response to induction therapy pre-
dicts for prognosis. In larger multi-institutional breast cancer trials, a
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pathologic complete response predicts for the very best prognosis. You
conclude that the best predictor is “a candidate for breast-conserving
therapy.” This looks a bit data-derived to me. Is this your new hypothesis?
Or is this the play of chance, Dr. Cance?
DR. WILLIAM G. CANCE (Chapel Hill, NC): Dr. Wood, I agree it is very
difficult to prove a survival advantage with a trial such as this, and I think
your point is well taken. It is even more difficult to prove that time intensity
matters. Some data from Dr. Bernard Fisher in the past has suggested that
metastases can grow more quickly after surgery in experimental animals.
That was one of the bases for our time-intense regimen of moving to the
next phase of chemotherapy 2 weeks after surgery. Hopefully, the CALGB
9741 trial, looking at time intensity comparisons, should answer some of
those questions.
Regarding the new contralateral cancers, these do not appear to be
metastases, but appear to be new primaries. We excluded the cross-chest
wall inflammatory cancers, so these should all be new primary cancers.
There were only eight T3N0 patients in the study, and they did not
appear to influence the survival curves. When we took those patients out
and ran the analyses, the distant disease-free survival was about 71%,
essentially equivalent to the entire group.
The pathological complete response does appear to be the best prognos-
tic factor from other studies, and I think that that would be the gold
standard for neoadjuvant therapy. We did not have the same level of
preoperative chemotherapy that the patients are currently getting as part of
other trials, and we did have distant disease develop in our pathological
complete responders. So, we suspect that the CMF had an impact when the
patients went back to the next phase of chemotherapy. So, we were perhaps
in an earlier end point where we couldn’ t pick up those patients who were
going to respond to the CMF. Since we couldn’ t measure response to the
CMF, our surrogate was a response to the doxorubicin chemotherapy by
downstaging to allow breast conservation. As you said, it is more data-
driven than hypothesis-driven. Nonetheless, I agree that the pathological
complete response is the current gold standard for a more favorable
long-term prognosis.
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